Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Starting soon Observational

A Multicenter Evaluation of SalivIQ™ Strep A for Detecting Group A Streptococcus From Saliva and Throat Swabs in Patients With Acute Pharyngitis

NCT07891728 · tracked via the Priya Life Science USA tracker
Sponsor
SalivIQ Diagnostics, Inc
Phase
Observational
Started
2026-10-09
Last updated
2026-10-28

Condition(s) studied

Streptococcal PharyngitisGroup A Streptococcal Infection

Investigational drug(s) / intervention(s)

qPCR

qPCR: molecular test

Study summary

The goal of this observational study is to learn how well the SalivIQ™ Strep A test detects Group A Streptococcus, the bacteria that cause strep throat. The study will include children and adults with symptoms that may be caused by strep throat.

The main questions this study aims to answer are:

* How well does the SalivIQ™ Strep A test identify participants who have strep throat?
* How well does the SalivIQ™ Strep A test identify participants who do not have strep throat?
* How do results from saliva and throat swab samples tested with the SalivIQ™ Strep A test compare with standard laboratory testing?

Participants will:

* Provide a saliva sample.
* Have throat swab samples collected.
* Have samples tested using the SalivIQ™ Strep A test and standard laboratory methods.

Researchers will compare the SalivIQ™ Strep A test results with standard laboratory test results to determine how accurately the test detects Group A Streptococcus. Participation in the study will not change the medical care participants receive based on their routine clinical testing.

Eligibility

Sex
ALL
Min age
3 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Adult patients (age 18 years or older) or minor patients (3-17 years) with an accompanying adult * Patient exhibits signs and symptoms of pharyngitis, such as sudden onset of sore throat, pain with swallowing, and fever * Willing and able to provide consent and assent to participate in the study Exclusion Criteria: * Prior antibiotic use within the past 7 days

Primary outcome measure(s)

  • Diagnostic Sensitivity of SalivIQ™ Strep A Using Saliva Specimens — Day 1
    Sensitivity of the SalivIQ™ Strep A test using saliva specimens for detection of Group A Streptococcus (GAS), compared with reference β-hemolytic GAS throat culture. Sensitivity will be calculated as the proportion of participants with a positive reference throat culture who also have a positive SalivIQ™ Strep A saliva result, with a two-sided 95% confidence interval.
  • Diagnostic Specificity of SalivIQ™ Strep A Using Saliva Specimens — Day 1
    Specificity of the SalivIQ™ Strep A test using saliva specimens for detection of Group A Streptococcus (GAS), compared with reference β-hemolytic GAS throat culture. Specificity will be calculated as the proportion of participants with a negative reference throat culture who also have a negative SalivIQ™ Strep A saliva result, with a two-sided 95% confidence interval.
  • Diagnostic Sensitivity of SalivIQ™ Strep A Using Throat Swab Specimens — Day 1
    Sensitivity of the SalivIQ™ Strep A test using throat swab specimens for detection of Group A Streptococcus (GAS), compared with reference β-hemolytic GAS throat culture. Sensitivity will be calculated as the proportion of participants with a positive reference throat culture who also have a positive SalivIQ™ Strep A throat swab result, with a two-sided 95% confidence interval.
  • Diagnostic Specificity of SalivIQ™ Strep A Using Throat Swab Specimens — Day 1
    Specificity of the SalivIQ™ Strep A test using throat swab specimens for detection of Group A Streptococcus (GAS), compared with reference β-hemolytic GAS throat culture. Specificity will be calculated as the proportion of participants with a negative reference throat culture who also have a negative SalivIQ™ Strep A throat swab result, with a two-sided 95% confidence interval.

Trial sites (3)

FacilityCityRegionStatus
American Family Care Baton Rouge Louisiana
American Family Care North Andover Massachusetts
PM Pediatrics Dallas Texas
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07891728 on ClinicalTrials.gov ↗ ← All trials in the USA